Business Wire

Q4

4.6.2024 14:01:34 CEST | Business Wire | Press release

Share
Q4 Inc. Research Uncovers Positive IRO Sentiment on AI in Investor Relations

Q4 Inc. (“Q4” or “the company”), the IR Ops platform, unveils survey results focused on a variety of topics to better understand Investor Relations Officers (“IROs”) goals, challenges and use cases within AI. Over 200 IROs engaged with the survey, providing in depth insight for what the future of IR may hold and a clear roadmap on how IR technology partners can help.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604548445/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Evolving Role of the IRO (Graphic: Business Wire)

With small teams and tight budgets, IR programs are laser focused on driving greater efficiency and effectiveness in their IR strategies. The top expectations from IR management to IROs are clear; shareholder retention, improving analyst ratings and coverage, and enhancing the quality of investor meetings. With the majority of IR teams composed of just a few members, these mandates are challenging to achieve. Therefore, this data solidifies the necessary need to deliver on these expectations in a timely, efficient, and effective way.

IROs were asked what tools they would use if they had unlimited resources to enhance their success. Over 50% of those surveyed expressed a desire for additional tools that provide impact reporting and progress tracking. This data corresponds with the top goals and challenges uncovered in the survey, with respondents identifying investor and analyst targeting/engagement as their primary goal and 40% of them reporting it as their biggest challenge. Furthermore, 43% of IROs stated that identifying the right individuals for outreach is their top challenge when trying to attract new investors.

Advancements in technology, particularly the use of AI, offer effective solutions for IROs to address these challenges. A significant majority (73%) of IROs believe in the potential of AI to make teams more effective and save time on administrative tasks, while 60% think AI will allow more time for strategic initiatives. However, there is still a gap in understanding and integrating technology effectively, as over 50% of respondents are unsure where AI would be most useful and how to best utilize it for success.

Darrell Heaps, Founder and CEO of Q4, stated, “Through our recent survey and in discussions with our existing clients, including members of our client advisory board, we understand the challenges that IROs face and are committed to providing them with the tools they need to succeed. In order to mitigate some of the issues IROs are facing, our research found that there is a need for education around how technology, including AI, can help to increase efficiency.”

Q4’s research substantiates the importance of the types of tools being used by IROs, how they access the knowledge to use them effectively, and how to measure and report outcomes when using AI. By automating routine IR tasks, IROs can devote more time and resources to strategic planning, fostering meaningful relationships and driving premium valuations, which are crucial for long-term success.

For additional information on the research conducted by Q4, please contact media@q4inc.com.

About Q4 Inc.

Q4 Inc. is the first IR Ops Platform with the world’s largest set of proprietary investor data, purpose-built to remove obstacles between public companies and their investors. Q4 gives investor relations leaders and their teams the tools to attract, manage, and understand investors — all in one place. The AI-enabled Q4 IR Ops Platform boasts a simple yet powerful IR website management system, frictionless events software, a robust analytics engine, a streamlined investor CRM, and shareholder intelligence with enhanced metrics to elevate investor targeting strategies. Q4 delivers the data, insights, and workflows that give IR teams the power to focus on what really matters: strategy, relationships, and driving premium valuations for their companies.

The company is a trusted partner to more than 2,600 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.

Q4 is headquartered in Toronto, with offices in New York and London. Learn more at www.q4inc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604548445/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye